FUNDAMENTALS · Fundamentals · US Healthcare

Fulgent Genetics (FLGT) Fundamentals 2026 — Revenue Analysis | SniperIQ

Fulgent Genetics (FLGT) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of $556M, trading at

9.56 on the NASDAQ. This SniperIQ fundamentals page covers Fulgent Genetics's valuation, profitability (net margin -23.0%), revenue (
23M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$556M
Net Margin-23.0%
Revenue (FY25)
23M

Full research coverage

Frequently Asked Questions

What is Fulgent Genetics's market cap?

Fulgent Genetics (FLGT) has a market capitalization of approximately $556M, trading at

9.56 on the NASDAQ. Market cap moves with the live share price.

What is Fulgent Genetics's P/E ratio?

Fulgent Genetics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Fulgent Genetics?

Fulgent Genetics runs a net profit margin of -23.0%, a gross margin of 38.7%, and an operating margin of -33.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Fulgent Genetics generate?

Fulgent Genetics reported revenue of

23M for fiscal year 2025, with net income of -$61M and earnings per share (EPS) of -1.97. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Fulgent Genetics pay a dividend?

Fulgent Genetics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Fulgent Genetics financially healthy?

Fulgent Genetics carries a debt-to-equity ratio of 0.01x and a current ratio of 5.31x, with a market beta of 0.89. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Fulgent Genetics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fulgent Genetics (FLGT) the key facts are: market cap $556M, revenue

23M, 52-week range 13.46-31.04. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Fulgent Genetics's full fundamentals live

Get Fulgent Genetics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.